Skip to main content
Erschienen in: Clinical and Translational Oncology 11/2016

08.02.2016 | Review Article

Regulation of epithelial–mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs

verfasst von: C. N. Kent, I. K. Guttilla Reed

Erschienen in: Clinical and Translational Oncology | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Endometrial cancer (EC) prognosis is dependent on many factors such as time of diagnosis, histological type, and degree of invasion. Type I EC has a more favorable prognosis as it is less prone to myometrial invasion, which is believed to be the first step in the metastatic cascade. Type II EC displays a more aggressive and motile phenotype, and therefore has a poorer prognosis. Recent work suggests that despite the epithelial nature of Type I and Type II endometrial tumors, both are capable of undergoing an epithelial–mesenchymal transition (EMT), which may facilitate myometrial invasion and metastasis. Activation of the PI3K/Akt pathway has been shown to contribute to EMT through the upregulation of EMT-associated factors. Recent research has also linked estrogen signaling and microRNAs to the regulatory mechanisms that drive EMT in EC. Understanding the intricate relationships between these pathways will provide a better understanding of metastatic progression in EC.
Literatur
3.
Zurück zum Zitat Cancer Facts and Figures 2016 (database on the Internet) 2015. Accessed 2016. Cancer Facts and Figures 2016 (database on the Internet) 2015. Accessed 2016.
5.
Zurück zum Zitat Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.CrossRefPubMed Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–7.CrossRefPubMed
8.
Zurück zum Zitat Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, et al. Lack of estrogen receptor-alpha is associated with epithelial–mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 2013;19(5):1094–105. doi:10.1158/1078-0432.CCR-12-3039.CrossRefPubMed Wik E, Raeder MB, Krakstad C, Trovik J, Birkeland E, Hoivik EA, et al. Lack of estrogen receptor-alpha is associated with epithelial–mesenchymal transition and PI3K alterations in endometrial carcinoma. Clin Cancer Res. 2013;19(5):1094–105. doi:10.​1158/​1078-0432.​CCR-12-3039.CrossRefPubMed
9.
Zurück zum Zitat Pessoa JN, Freitas AC, Guimaraes RA, Lima J, Dos Reis HL, Filho AC. Endometrial assessment: when is it necessary? J Clin Med Res. 2014;6(1):21–5. doi:10.4021/jocmr1684w.PubMed Pessoa JN, Freitas AC, Guimaraes RA, Lima J, Dos Reis HL, Filho AC. Endometrial assessment: when is it necessary? J Clin Med Res. 2014;6(1):21–5. doi:10.​4021/​jocmr1684w.PubMed
13.
14.
Zurück zum Zitat Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010;220(5):551–61. doi:10.1002/path.2673.CrossRefPubMed Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010;220(5):551–61. doi:10.​1002/​path.​2673.CrossRefPubMed
19.
20.
Zurück zum Zitat Hou X, Zhao M, Wang T, Zhang G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol Rep. 2014;31(3):1175–82. doi:10.3892/or.2013.2944.PubMed Hou X, Zhao M, Wang T, Zhang G. Upregulation of estrogen receptor mediates migration, invasion and proliferation of endometrial carcinoma cells by regulating the PI3K/AKT/mTOR pathway. Oncol Rep. 2014;31(3):1175–82. doi:10.​3892/​or.​2013.​2944.PubMed
22.
Zurück zum Zitat Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63(9):2172–8.PubMed Grille SJ, Bellacosa A, Upson J, Klein-Szanto AJ, van Roy F, Lee-Kwon W, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 2003;63(9):2172–8.PubMed
24.
Zurück zum Zitat Farnell YZ, Ing NH. Endometrial effects of selective estrogen receptor modulators (SERMs) on estradiol-responsive gene expression are gene and cell-specific. J Steroid Biochem Mol Biol. 2003;84(5):513–26.CrossRefPubMed Farnell YZ, Ing NH. Endometrial effects of selective estrogen receptor modulators (SERMs) on estradiol-responsive gene expression are gene and cell-specific. J Steroid Biochem Mol Biol. 2003;84(5):513–26.CrossRefPubMed
26.
Zurück zum Zitat Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 2006;99(1):9–18. doi:10.1016/j.jsbmb.2005.11.013.CrossRefPubMed Guo RX, Wei LH, Tu Z, Sun PM, Wang JL, Zhao D, et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 2006;99(1):9–18. doi:10.​1016/​j.​jsbmb.​2005.​11.​013.CrossRefPubMed
28.
Zurück zum Zitat Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat. 2012;132(1):75–85. doi:10.1007/s10549-011-1534-y.CrossRefPubMed Guttilla IK, Phoenix KN, Hong X, Tirnauer JS, Claffey KP, White BA. Prolonged mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by microRNAs. Breast Cancer Res Treat. 2012;132(1):75–85. doi:10.​1007/​s10549-011-1534-y.CrossRefPubMed
29.
Zurück zum Zitat Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.PubMed Thigpen T, Brady MF, Homesley HD, Soper JT, Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2001;19(2):364–7.PubMed
30.
Zurück zum Zitat Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2(8):536–44. doi:10.1021/cb700072n.CrossRefPubMed Revankar CM, Mitchell HD, Field AS, Burai R, Corona C, Ramesh C, et al. Synthetic estrogen derivatives demonstrate the functionality of intracellular GPR30. ACS Chem Biol. 2007;2(8):536–44. doi:10.​1021/​cb700072n.CrossRefPubMed
32.
33.
Zurück zum Zitat Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015;43:42–60. doi:10.1016/j.matbio.2015.02.008.CrossRefPubMed Bouris P, Skandalis SS, Piperigkou Z, Afratis N, Karamanou K, Aletras AJ, et al. Estrogen receptor alpha mediates epithelial to mesenchymal transition, expression of specific matrix effectors and functional properties of breast cancer cells. Matrix Biol. 2015;43:42–60. doi:10.​1016/​j.​matbio.​2015.​02.​008.CrossRefPubMed
34.
Zurück zum Zitat Xia H, Hui KM. MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012;19(11):723–30. doi:10.1038/cgt.2012.58.CrossRefPubMed Xia H, Hui KM. MicroRNAs involved in regulating epithelial–mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Cancer Gene Ther. 2012;19(11):723–30. doi:10.​1038/​cgt.​2012.​58.CrossRefPubMed
38.
Zurück zum Zitat Wu KJ. Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial–mesenchymal transition, and clinical significance. Chang Gung Med J. 2011;34(3):229–38.PubMed Wu KJ. Direct activation of Bmi1 by Twist1: implications in cancer stemness, epithelial–mesenchymal transition, and clinical significance. Chang Gung Med J. 2011;34(3):229–38.PubMed
39.
Zurück zum Zitat Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130(5):1036–45. doi:10.1002/ijc.26060.CrossRefPubMed Chung TK, Lau TS, Cheung TH, Yim SF, Lo KW, Siu NS, et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer. 2012;130(5):1036–45. doi:10.​1002/​ijc.​26060.CrossRefPubMed
41.
Zurück zum Zitat Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial–mesenchymal transition. Cell Cycle. 2008;7(20):3112–8.CrossRefPubMed Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial–mesenchymal transition. Cell Cycle. 2008;7(20):3112–8.CrossRefPubMed
43.
44.
Zurück zum Zitat Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, Biscuola M, Castilla MA, Tafe LJ, et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 2013;26(11):1514–24. doi:10.1038/modpathol.2013.93.CrossRefPubMed Romero-Perez L, Lopez-Garcia MA, Diaz-Martin J, Biscuola M, Castilla MA, Tafe LJ, et al. ZEB1 overexpression associated with E-cadherin and microRNA-200 downregulation is characteristic of undifferentiated endometrial carcinoma. Mod Pathol. 2013;26(11):1514–24. doi:10.​1038/​modpathol.​2013.​93.CrossRefPubMed
46.
Metadaten
Titel
Regulation of epithelial–mesenchymal transition in endometrial cancer: connecting PI3K, estrogen signaling, and microRNAs
verfasst von
C. N. Kent
I. K. Guttilla Reed
Publikationsdatum
08.02.2016
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 11/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1492-2

Weitere Artikel der Ausgabe 11/2016

Clinical and Translational Oncology 11/2016 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.